|
The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma Clinical research trials and The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma. The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma clinical trial. Test subjects typically obtain the finest healthcare available for their The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma  The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma
The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma
For Condition: Sarcoma, Kaposi,HIV Infections
Status: Completed
Sponsor(s): Abbott Laboratories ,
Synopsis: To evaluate the safety and anti-Kaposi's sarcoma activity of ritonavir.
Details:
Eligibility:
Study Type: Interventional, Treatment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Patients may receive oral acyclovir and may continue prophylactic treatment for PCP, fungal infection, MAC and toxoplasmosis. - Topical treatment and intralesional chemotherapy will be allowed for lesions which will not be used as indicator or biopsy lesions. Concurrent Treatment: Allowed: Localized radiotherapy will be allowed for lesions which will not be used as indicator or biopsy lesions. Patients must have: - Documentation of a positive ELISA test for HIV with a confirmatory test. - Biopsy proven, cutaneous or oropharyngeal Kaposi's sarcoma. - Vital signs, physical examination and laboratory assessments that exhibit no evidence of an acute illness. - Patients must agree to report all current medications to the primary investigator and obtain prior permission to use them when feasible. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: - Evidence of pulmonary Kaposi's sarcoma. - Positive urine screen for recreational drugs. - Current participation in another antiviral research study. - Investigator anticipates poor patient compliance with the protocol. - Patient has any condition that, in the investigator's opinion, may obscure the proper observation of the safety or activity of ritonavir. Concurrent Medication: Excluded: - Antiretroviral therapy. - Protease inhibitor therapy. - Antiviral agent (e.g., oral ganciclovir or Foscarnet) or prophylactic medication for an AIDS defining illness which the patient cannot be removed from. - Chemotherapy for Kaposi's sarcoma. - Treatment with any medications that may interact with ritonavir. Concurrent Treatment: Excluded: Radiotherapy for Kaposi's sarcoma. Patients with any of the following prior conditions are excluded: - History of psychiatric illness which is currently medically significant. - History of pancreatitis. Prior Medication: Excluded: - All antiretrovial therapy within 2 weeks prior to the start of the treatment phase of the study. - Systemic chemotherapy of interferon within 30 days prior to study entry. - Previous treatment with a protease inhibitor. Risk Behavior: Excluded: Active substance abuse.
Total Enrollment:
Location and Contact Information:
Saint Vincent's Hosp Med Centre
Sydney, ,
Australia
Prince Henry's Hosp / Med Oncology
Sydney, ,
Australia
Additional Information:
Study ID Numbers: 245C; M95-320
Study Start Date:
Record last reviewed: July 1997
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002366
Other Sarcoma, Kaposi Studies:
1. The Effectiveness of Cow's Milk Immune Globulin in the Treatment of AIDS-Related Diarrhea
2. Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
3. The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants
4. A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected with HIV-1
5. A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
Related Studies:
Other Sarcoma, Kaposi Clinical Trials
Other Clinical Trials
Other Sydney Clinical Trials
The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma
|
|
|
|
|
|
|
|
